Singapore, Aug 19, 2010: Australian health care company, Prima BioMed, has announced the appointment of Dr Sharron Gargosky as Senior Vice President for the company’s CVac clinical programs.

 

Dr Gargosky brings 18 years experience in the biotechnology and pharmaceutical industries, and has worked in senior positions for three different companies which have successfully received FDA approval for orphan drugs.

Dr Gargosky will be based in United States, and will be a key senior member of Prima’s world class executive team. In her new position, Dr Gargosky will be responsible for managing the clinical team working on the CVac immunotherapy cancer vaccine. This will be a pivotal role within the company, as it embarks on its late stage clinical trials for CVac.

 

Prior to joining Prima, Dr Gargosky was a member of Member of ILMU Consulting. In this role, she provided project management and operational expertise in the area of pharmaceutical drug and biologic development – from the early research phase, through to phase IV trials and the FDA approval process.

Commenting on Dr Gargosky’s appointment, Prima BioMed’s Managing Director Martin Rogers said: “I am delighted to welcome Dr Gargosky to the Prima team. Her depth of experience and expertise in the development process of new drug candidates particularly Orphan Drug designated candidates, is of an extremely high standard, and will be invaluable as we progress our CVac clinical programs.”